Interactive or static reports to guide clinical interpretation of cancer genomics

Abstract Objective Misinterpretation of complex genomic data presents a major challenge in the implementation of precision oncology. We sought to determine whether interactive genomic reports with embedded clinician education and optimized data visualization improved genomic data interpretation. Materials and Methods We conducted a randomized, vignette-based survey study to determine whether exposure to interactive reports for a somatic gene panel, as compared to static reports, improves physicians’ genomic comprehension and report-related satisfaction (overall scores calculated across 3 vignettes, range 0–18 and 1–4, respectively, higher score corresponding with improved endpoints). Results One hundred and five physicians at a tertiary cancer center participated (29% participation rate): 67% medical, 20% pediatric, 7% radiation, and 7% surgical oncology; 37% female. Prior to viewing the case-based vignettes, 34% of the physicians reported difficulty making treatment recommendations based on the standard static report. After vignette/report exposure, physicians’ overall comprehension scores did not differ by report type (mean score: interactive 11.6 vs static 10.5, difference = 1.1, 95% CI, −0.3, 2.5, P = .13). However, physicians exposed to the interactive report were more likely to correctly assess sequencing quality (P < .001) and understand when reports needed to be interpreted with caution (eg, low tumor purity; P = .02). Overall satisfaction scores were higher in the interactive group (mean score 2.5 vs 2.1, difference = 0.4, 95% CI, 0.2-0.7, P = .001). Discussion and Conclusion Interactive genomic reports may improve physicians’ ability to accurately assess genomic data and increase report-related satisfaction. Additional research in users’ genomic needs and efforts to integrate interactive reports into electronic health records may facilitate the implementation of precision oncology.

[1]  Peter Tarczy-Hornoch,et al.  Refining the structure and content of clinical genomic reports , 2014, American journal of medical genetics. Part C, Seminars in medical genetics.

[2]  R. Croyle,et al.  Physician use of genetic testing for cancer susceptibility: results of a national survey. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[3]  Jonathan M Marron,et al.  Pediatric Oncology Provider Views on Performing a Biopsy of Solid Tumors in Children with Relapsed or Refractory Disease for the Purpose of Genomic Profiling , 2016, Annals of Surgical Oncology.

[4]  Lee T. Sam,et al.  Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study , 2011, Science Translational Medicine.

[5]  D. Bates,et al.  Appropriateness: A Key to Enabling the Use of Genomics in Clinical Practice? , 2016, American Journal of Medicine.

[6]  Moriah H Nissan,et al.  OncoKB: A Precision Oncology Knowledge Base. , 2017, JCO precision oncology.

[7]  N. Holtzman,et al.  Does knowledge about the genetics of breast cancer differ between nongeneticist physicians who do or do not discuss or order BRCA testing? , 2003, Genetics in Medicine.

[8]  Carrie Cibulskis,et al.  Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study , 2017, Genetics in Medicine.

[9]  Razelle Kurzrock,et al.  Breast Cancer Experience of the Molecular Tumor Board at the University of California, San Diego Moores Cancer Center. , 2015, Journal of oncology practice.

[10]  Marie-Cécile Le Deley,et al.  High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. , 2017, Cancer discovery.

[11]  Nicolas Servant,et al.  Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. , 2015, The Lancet. Oncology.

[12]  Christopher G. Chute,et al.  CSER and eMERGE: current and potential state of the display of genetic information in the electronic health record , 2015, J. Am. Medical Informatics Assoc..

[13]  S. Kamel‐Reid,et al.  Postal survey of physicians and laboratories: Practices and perceptions of molecular oncology testing , 2009, BMC health services research.

[14]  Tao Wang,et al.  Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors. , 2016, JAMA oncology.

[15]  L. Macconaill,et al.  Validation of OncoPanel: A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer. , 2017, Archives of pathology & laboratory medicine.

[16]  E. Smets,et al.  Non-genetic health professionals’ attitude towards, knowledge of and skills in discussing and ordering genetic testing for hereditary cancer , 2015, Familial Cancer.

[17]  Andy Anderson,et al.  Physicians' preparedness for integration of genomic and pharmacogenetic testing into practice within a major healthcare system. , 2013, Genetic testing and molecular biomarkers.

[18]  C. Ponting,et al.  Sequencing depth and coverage: key considerations in genomic analyses , 2014, Nature Reviews Genetics.

[19]  G. Abel,et al.  Increasing response rates from physicians in oncology research: a structured literature review and data from a recent physician survey , 2012, British Journal of Cancer.

[20]  Marc S. Williams,et al.  Enhancing genomic laboratory reports: A qualitative analysis of provider review , 2016, American journal of medical genetics. Part A.

[21]  E. V. Van Allen,et al.  Next-generation sequencing to guide cancer therapy , 2015, Genome Medicine.

[22]  Robert C. Green,et al.  Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the Clinical Sequencing Exploratory Research Consortium , 2013, Genetics in Medicine.

[23]  K. Nichols,et al.  Integrating next‐generation sequencing into pediatric oncology practice: An assessment of physician confidence and understanding of clinical genomics , 2017, Cancer.

[24]  Gary D Bader,et al.  Computational approaches to identify functional genetic variants in cancer genomes , 2013, Nature Methods.

[25]  Joshua S. Paul,et al.  Genotype and SNP calling from next-generation sequencing data , 2011, Nature Reviews Genetics.

[26]  Donavan T. Cheng,et al.  Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.

[27]  Jane C Weeks,et al.  Physicians' attitudes about multiplex tumor genomic testing. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Matthew S. Lebo,et al.  A systematic approach to the reporting of medically relevant findings from whole genome sequencing , 2014, BMC Medical Genetics.

[29]  Gavin R. Oliver,et al.  Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery , 2017, Oncotarget.

[30]  Matthew S. Lebo,et al.  A survey of informatics approaches to whole-exome and whole-genome clinical reporting in the electronic health record , 2013, Genetics in Medicine.

[31]  William Pao,et al.  DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): A Catalog of Clinically Relevant Cancer Mutations to Enable Genome-Directed Anticancer Therapy , 2013, Clinical Cancer Research.

[32]  Nikhil Wagle,et al.  The fuzzy world of precision medicine: deliberations of a precision medicine tumor board , 2016, Personalized medicine.

[33]  Ira M. Lubin,et al.  Effective communication of molecular genetic test results to primary care providers , 2012, Genetics in Medicine.

[34]  R. Green,et al.  Genomic sequencing in clinical practice: applications, challenges, and opportunities , 2016, Dialogues in clinical neuroscience.

[35]  Denise L. Perry,et al.  Are physicians prepared for whole genome sequencing? a qualitative analysis , 2016, Clinical genetics.

[36]  Steven J. M. Jones,et al.  CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer , 2017, Nature Genetics.

[37]  L. Garraway,et al.  Oncologists' and Cancer Patients' Views on Whole-Exome Sequencing and Incidental Findings: Results from The CanSeq Study , 2016, Genetics in Medicine.

[38]  Levi A Garraway,et al.  Genomics-driven oncology: framework for an emerging paradigm. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Marian Harris,et al.  Institutional implementation of clinical tumor profiling on an unselected cancer population. , 2016, JCI insight.